miR‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets

BACKGROUND: Malignant cell growth and chemoresistance, the main obstacles in treating gastrointestinal cancer (GIC), rely on the Hippo and p53 signalling pathways. However, the upstream regulatory mechanisms of these pathways remain complex and poorly understood. METHODS: Immunohistochemistry (IHC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ling, Guo, Hui, Liao, Quan, Zou, Jianping, Le, Yi, Fang, Ziling, Xiong, Jianping, Huang, Shanshan, Deng, Jun, Xiang, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568676/
https://www.ncbi.nlm.nih.gov/pubmed/37555915
http://dx.doi.org/10.1111/jcmm.17880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568676/
https://www.ncbi.nlm.nih.gov/pubmed/37555915
http://dx.doi.org/10.1111/jcmm.17880

Ejemplares similares